Cabenuva

Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population

Cabenuva / By

This study aimed to describe the frequency of virologic factors that previously influenced the efficacy of this treatment, namely RPV and CAB resistance-associated mutations.

Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population Read More »

Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South

Cabenuva / By

Long-acting injectable (LAI) antiretroviral therapy (ART) has the potential to improve medication adherence, reduce human immunodeficiency virus (HIV) stigma, and promote equity in care outcomes among people with HIV (PWH). We describe our early experience implementing LAI-cabotegravir/rilpivirine (CAB/RPV) for maintenance HIV-1 treatment.

Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South Read More »

Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study

Cabenuva / By

The CUSTOMIZE hybrid III implementation-effectiveness study evaluated implementation of once-monthly long-acting (LA) cabotegravir + rilpivirine in diverse US healthcare settings. Here, we report patient participant perspectives after 12 months in CUSTOMIZE.

Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study Read More »

Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)

Cabenuva / By

CUSTOMIZE evaluated the implementation of long-acting (LA) cabotegravir + rilpivirine, a novel healthcare provider–administered injectable antiretroviral therapy regimen, in diverse US healthcare settings. Findings from staff-study participants (SSPs) through 12 months of implementation are reported.

Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE) Read More »

An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV

Cabenuva / By

The approval of intramuscular cabotegravir (CAB) and rilpivirine (RPV) offers a new therapeutic modality with the opportunity of a longer dosing frequency. The data from recent trials including FLAIR and ATLAS have shown non-inferiority in treatment based on the current standard of care. This approval has the potential to simplify patient medication regimens, while maintaining

An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV Read More »

Case: Successful Viral Suppression Using a Fully Injectable ART Combination Therapy of Ibalizumab + Cabotegravir/Rilpivirine in an HIV+ Patient with Malabsorption

Cabenuva, Trogarzo / By

Malabsorption in patients with HIV (PWH) can lead to decreased antiretroviral (ARV) drug exposure which may induce viral failure and emergence of resistance mutations When treating PWH with malabsorption, it is important to avoid oral administration of antiretroviral therapies (ARTs) and switch them to parenteral agents, which bypass the gastrointestinal system

Case: Successful Viral Suppression Using a Fully Injectable ART Combination Therapy of Ibalizumab + Cabotegravir/Rilpivirine in an HIV+ Patient with Malabsorption Read More »

Scroll to Top